Retina · 2011 · 57 citations · 39 references
MedicineOphthalmologyPharmacotherapyOcular DiseaseOcular PharmacologyOphthalmic SurgeryChoroidal AnatomyIndocyanine Green AngiographyRetinal ImagingRetinal PharmacotherapyRetinal Vascular DiseaseVisual Loss EvaluationAngiographic SuccessIndocyanine Green ImagingRetinal Layer ThicknessRetinal Thickness AnalysisSnellen AcuitySnellen Chart ScreeningStatic Visual AcuityVisual Acuity Monitoring
PURPOSE: To report on 1-year visual, anatomical, and angiographic responses with intravitreal bevacizumab for the treatment of polypoidal choroidal vasculopathy. METHODS: Patients with macula-involved, symptomatic polypoidal choroidal vasculopathy with initial best-corrected visual acuity of 20/400 or better and a minimal follow-up period of 12 months were retrospectively enrolled. Eyes were treated with intravitreal bevacizumab (2.5 mg) at baseline and monitored monthly for best-corrected visual acuity and central retinal thickness (by optical coherence tomography). Indocyanine green angiography was evaluated on a 6-month basis. Eyes were retreated on an "as-needed" basis according to visual and anatomical changes. RESULTS: A total of 35 eyes of 33 patients were treated with a mean of 3.3 (range, 1-8) times of injection. Best-corrected visual acuity significantly improved from a mean logarithm of the minimum angle of resolution of 0.79 ± 0.42 at baseline (Snellen equivalent, 20/123) to 0.69 ± 0.47 (20/94), 0.66 ± 0.45 (20/87), 0.67 ± 0.44 (20/87), 0.67 ± 0.48 (20/87), and 0.67 ± 0.51 (20/87) at 1, 3, 6, 9, and 12 months, respectively (P = 0.002, 0.0003, 0.0008, 0.017, and 0.02, respectively; paired Student's t-test). Central retinal thickness also significantly improved from a mean of 297 ± 94 μm at baseline to 215 ± 58 μm, 214 ± 59 μm, 218 ± 79 μm, 213 ± 75 μm, and 221 ± 61 μm at 1, 3, 6, 9, and 12 months, respectively (all P < 0.0001, paired Student's t-test). Indocyanine green angiography showed 3 of 32 eyes (9.4%) and 5 of 31 eyes (16.1%) with completely resolved polyps and 11 of 32 eyes (34.4%) and 10 of 31 eyes (32.3%) with reduced polyps at 6 and 12 months, respectively. No systemic complication or severe local complication, such as endophthalmitis, was found. CONCLUSION: Intravitreal bevacizumab therapy has a favorable outcome in improving visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy. It can also moderately reduce polypoidal lesions on indocyanine green angiography.
39
Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld et al. · American Journal of Ophthalmology · 2007 · 972 citations
IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
Lawrence A. Yannuzzi, John A. Sorenson, Richard F. Spaide et al. · Retina · 2012 · 759 citations
INDOCYANINE GREEN VIDEOANGIOGRAPHY OF IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY
Richard F. Spaide, Lawrence A. Yannuzzi, Jason S. Slakter et al. · Retina · 1995 · 612 citations
IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
Lawrence A. Yannuzzi, John A. Sorenson, Barry K. Lipson · Retina · 1990 · 589 citations
Polypoidal Choroidal Vasculopathy
Chui Ming Gemmy Cheung, Timothy Y. Y. Lai, Kelvin Yi Chong Teo et al. · Ophthalmology · 2020 · 512 citations · Full text